TSE:TRL - Trilogy International Partners Stock Price, Forecast & News

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

Trilogy International Partners declared an annual dividend on Monday, April 15th. Investors of record on Monday, May 6th will be given a dividend of 0.02 per share on Monday, May 6th. This represents a yield of 0.86%. The ex-dividend date is Monday, April 15th. View Trilogy International Partners' Dividend History.

Trilogy International Partners Inc (TSE:TRL) released its earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The specialty pharmaceutical company earned $213.36 million during the quarter, compared to the consensus estimate of $237.60 million. View Trilogy International Partners' Earnings History.

Trilogy International Partners is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Trilogy International Partners.

2 equities research analysts have issued 12 month price targets for Trilogy International Partners' stock. Their forecasts range from C$3.25 to C$3.50. On average, they anticipate Trilogy International Partners' share price to reach C$3.38 in the next year. This suggests a possible upside of 73.1% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.

News articles about TRL stock have been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trilogy International Partners earned a coverage optimism score of 2.9 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Trilogy International Partners.

Some companies that are related to Trilogy International Partners include Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Allergy Therapeutics (AGY), Pharmaxis (PXS), Recce Pharmaceuticals (RCE), Vita Life Sciences (VLS), Patrys (PAB), Futura Medical (FUM), Antisense Therapeutics (ANP), Avivagen (VIV), Sareum (SAR), NanoViricides (NNVC), Cathay International (CTI), China Pharma (CPHI) and N4 Pharma (N4P).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Millicom International Cellular (MIICF), Oncolytics Biotech (ONCYF), Emera (EMA), Glacier Bancorp (GBCI), Fibrocell Science (FCSC), CytomX Therapeutics (CTMX), CSX (CSX), Check Cap (CHEK) and Buffalo Wild Wings (BWLD).

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

One share of TRL stock can currently be purchased for approximately C$1.95.

Trilogy International Partners has a market capitalization of C$113.74 million and generates C$734.77 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.View Additional Information About Trilogy International Partners.

The official website for Trilogy International Partners is http://www.trilogy-international.co.../.

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.